ASPC 10-K & 10-Q changes, risk factors and insider trading
ASPAC III Acquisition Corp. (also ASPCR, ASPCU) · Nasdaq · Blank Checks · CIK 1890361 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
As a smaller reporting company, we are not required to include risk factors in this Annual Report.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
New heading “Merger Agreement”
Largest changes
“On October 27, 2025, the Company convened its extraordinary general meeting (the “2025 EGM”) at which the shareholders voted pursuant to the definitive proxy statement, filed by the Company with the Securities and Exchange Commission on October 10, 2025 and mailed by the Company to its shareholders on or about October 10, 2025.”see in full comparison
“The Merger Agreement contains customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain conditions as further described in the Merger Agreement.”see in full comparison
“The Merger Agreement contains customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain conditions as further described in the Merger Agreement.”see in full comparison
“Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. …”see in full comparison
The Companysee in full comparisonaccountedaccounts foritsClass A ordinary shares subject to possible redemption in accordance with the guidance in ASCTopic480.480,Class“Distinguishing LiabilitiesAfrom Equity” (ASC 480). Ordinaryordinary shares subject to mandatory redemption (if any)will beis classified as a liability instrument andwill beis measured at fair value. Conditionally redeemable ordinary shares (including ordinary shares thatfeaturesfeature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control)will beare classified as temporary equity. At all other times, ordinary shareswill beare classified asshareholder’sstockholders’ equity.In accordance with ASC 480-10-S99, the Company classified theThe Class A ordinary shares feature certain redemption rights that are considered to be outside of the Company’s control and subject toredemptiontheoutsideoccurrence ofpermanentuncertain future events. In accordance with the SEC and its guidance on redeemable equityasinstruments,thewhich has been codified in ASC 480-10-S99, redemption provisionsarenot solely within the control ofthea companyCompany.requireAsordinary shares subject to redemption to be classified outside ofNovemberpermanent19,equity.2024, givenGiven that the 6,000,000 Class A ordinary shares(inclusive of the partial exercise of the underwriter’s over-allotment option)sold as part of theunits in theCompany’s IPO were issued with other freestanding instruments (i.e.,rightsPublic Rights), the initial carrying value of Class A ordinary shares classified as temporary equitywashas been allocated to theallocatedproceeds determined in accordance with ASC 470-20. The Company’s Class A ordinary shares are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes in redemption valueasinaadditional paid-inchargecapitalagainst(orretainedaccumulatedearnings or,deficit in the absence ofretained earnings, as a charge againstadditionalpaid-in-capitalpaid-in capital) over an expected 12-month period, which is the initial periodleadingthatupthe Company has to complete abusinessBusinesscombination.Combination.
Full comparison: every changed paragraph (40)
On
November 12, 2024, the Company consummated its Initial Public Offering (“IPO”) and sold 5,500,000 Units. Each Unit consists
of one Class A ordinary share and one Right to receive one-tenth of one Class A ordinary share upon the consummation of an initial Business
Combination. The Units were sold at a price of $10.00 per unit, generating gross proceeds to the Company of $55,000,000.
Simultaneously
with the closing of the IPO and the sale of the Units, the Company consummated the Private Placement of an aggregate 280,000 Private
Placement Units.
Subsequently,
on November 15, 2024, Maxim notified the Company of their election to partially exercise their over-allotment option. The closing of
the issuance and sale of the additional Units occurred (the “Over-Allotment Option Units”) on November 19, 2024. The total
aggregate issuance by the Company of 500,000 Over-Allotment Option Units at the price of $10.00 per unit generated total gross proceeds
of $5,000,000. On November 19, 2024, simultaneously with the closing and sale of the Over-Allotment Option Units, the Company consummated
the private sale of an additional 5,000 Private Placement Units to the Sponsor, generating gross proceeds of $50,000.
In
connection with the IPO and issuance and sales of the Over-Allotment Option Units, the Company issued to Maxim, an aggregate of 270,000
Class A ordinary shares for no consideration (the “Representative Shares”).
As
a result of the underwriter’s partial exercise of the over-allotment option on November 19, 2024, 81,250 shares of Class B ordinary
share were forfeited for no consideration.
Upon
closing of the IPO, the Private Placement, and the sale of the Over-Allotment Option Units, a total of $60,000,000 was placed in the
Trust Account established for the benefit of our public shareholders and the underwriters of the IPO with Continental Stock Transfer
& Trust Company acting as trustee.
Total
transaction costs related to the offering amounted to $1,600,217 consisting of $600,000 of cash underwriting commissions which was paid
in cash at the closing date of the IPO and the sale of the Over-Allotment Option Units, $675,000 fair value of the Representative Shares,
and $325,217 of other offering costs.
On
December 31, 2024, the
Company entered into an agreement with HDEducation Group Limited, a Cayman Islands exempted company (“HD
Group”) (the “HD
Group Agreement”). HD Group is headquartered in Anji County, China, and is a comprehensive service
platform for students pursuing
university education globally. The Agreement is intended to express a mutual indication of interest, and
remains subject, in all respect,
to the execution of definitive agreements. Pursuant to the terms of the Agreement, the aggregate consideration
to be paid to existing
shareholders of HD Group is $300,000,000, which will be paid entirely in stock, comprised of newly issued Class
A ordinary shares and
Class B ordinary shares of A SPAC III Mini Acquisition Corp., a then to-be-formed British Virgin Islands business company
and the Company’s its
wholly owned subsidiary (the “PurchaserPubCo”) at a price of $10.00 per share. On May 21, 2025, the HD Group Agreement was terminated
by mutual agreement by the Company and HD Group.
On
January 24, 2025, the Company
entered into an a agreement with Bioserica International Limited, a British Virgin Islands business company
(“Bioserica”) (the
“Bioserica Agreement”). Bioserica is in the business of researching and developing, manufacturing,
marketing and sales of
bio-based antimicrobial materials. The Agreement is intended to express a mutual indication of interest, reflects
additional terms negotiated,
and remains subject, in all respect, to the execution of definitive agreements. The Agreement is intended
to express a mutual indication of interest, and remains subject, in all respect, to the execution of definitive agreements. Pursuant
to the terms of the Agreement, the aggregate consideration to be paid to existing shareholders of Bioserica is $200,000,000, which will
be paid entirely in stock, comprised of newly issued Class A ordinary shares and Class B ordinary shares of the Purchaser at a price
of $10.00 per share.
On May 23, 2025, the Company entered into a merger agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) with (i) Bioserica, (ii) PubCo, and (iii) A SPAC III Mini Sub Acquisition Corp., a British Virgin Islands business company formed as a wholly owned subsidiary of PubCo on February 3, 2025 (“Merger Sub”).
Pursuant to the Merger Agreement, among other things, (i) the Company will merge with and into PubCo, the separate corporate existence will cease and PubCo will continue as the surviving corporation (the “Reincorporation Merger”), and (ii) the Merger Sub will merge with and into Bioserica and Bioserica will continue as the surviving company under the laws of the British Virgin Islands and become a wholly owned subsidiary of PubCo (the “Acquisition Merger”). Pursuant to the terms of the Merger Agreement, the aggregate consideration for the Acquisition Merger is $217,860,000, consisting of (i) $200,000,000, payable in the form of 20,000,000 newly issued PubCo Class B ordinary shares, valued at $10.00 per share; and (ii) $17,860,000, payable in the form of 1,786,000 newly issued PubCo Class A ordinary shares, valued at $10.00 per share (assuming that Bioserica would receive an aggregate of $12,500,000 investment from third parties prior to Closing).
The Merger Agreement contains customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain conditions as further described in the Merger Agreement.
The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Merger Agreement, a copy of which is filed as Exhibit 2.1 to the Current Report on Form 8-K filed on May 27, 2025, and incorporated by reference herein.
Concurrently with the execution of the Merger Agreement, Bioserica, PubCo, the Company and a shareholder of Bioserica (the “Supporting Shareholder”) entered into a voting and support agreement (“Voting and Support Agreement”) pursuant to which such the Supporting Shareholder has agreed, among other things, to vote in favor of the Acquisition Merger, the adoption of the Merger Agreement and any other matters necessary or reasonably requested by Bioserica, PubCo or the Company for consummation of the Acquisition Merger and the other transactions contemplated by the Merger Agreement. In addition, the Supporting Shareholder has agreed not to sell, assign, encumber, pledge, hypothecate, dispose, loan or otherwise transfer the shares of the Company owned of record and beneficially by such Supporting Shareholder or over which such Supporting Shareholder has voting power, prior to the earlier to occur of (a) the closing of the Acquisition Merger, (b) the termination of the Merger Agreement, and (c) written agreement of the Supporting Shareholder, on the one hand, and the Company and PubCo, on the other hand.
On September 10, 2025, the Company completed an internal reorganization, pursuant to which Merger Sub became a wholly owned subsidiary of the Company (the “Reorganization”). As part of the Reorganization, PubCo transferred 100% of the issued and outstanding equity of Merger Sub to the Company.
On October 27, 2025, the Company convened its extraordinary general meeting (the “2025 EGM”) at which the shareholders voted pursuant to the definitive proxy statement, filed by the Company with the Securities and Exchange Commission on October 10, 2025 and mailed by the Company to its shareholders on or about October 10, 2025.
As of October 6, 2025, the record date for the 2025 EGM, there were 8,055,000 ordinary shares outstanding and entitled to vote. At the 2025 EGM, there were 7,113,684 ordinary shares voted by proxy or in person, representing 88.31% of the total ordinary shares as of the record date, and constituting a quorum for the transaction of business. The shareholders approved the Extension Amendment Proposal, and the Company filed the amended and restated memorandum and articles of Association (the “Amended Charter”) with the Registrar of Corporate Affairs at the British Virgin Islands. Pursuant to the Amended Charter which is effective on October 27, 2025, the Company has up to 24 months from its initial public offering (i.e., until November 12, 2026) to consummate an initial business combination. The Amended Charter was filed as an exhibit to the Current Report on Form 8-K, filed on October 27, 2025.
In connection with the shareholders’ vote at the 2025 EGM, 5,717,419 additional Class A ordinary shares were redeemed for $59,502,058. Immediately after the redemption, there was approximately $2.9 million remaining in the Trust Account and Sponsor holds approximately 76.4% of the Company’s 2,337,581 outstanding ordinary shares.
On October 25, 2025, the Sponsor entered into an assignment of economic interest agreement (the “Assignment of Economic Interest Agreement”) with an unaffiliated third party. In exchange for such third party agreeing to vote 621,084 shares of the Company’s Class A ordinary shares sold in its initial public offering in favor of the proposal to amend and restate the Company’s amended and restated memorandum and articles of association to allow the Company to extend the date by which it has to consummate a business combination for an additional twelve (12) months from November 12, 2025 to November 12, 2026 (the “Charter Amendment Proposal”), the Sponsor agreed to transfer to such third party or third parties an aggregate of 100,000 shares of the Company’s Class B ordinary shares held by the Sponsor immediately following the release or expiration of any transfer restrictions after the consummation of an initial business combination.
On January 16, 2026, pursuant to the Exchange Agreement between the Company and the Sponsor, the Sponsor transferred and delivered to the Company 1,499,900 Class B ordinary shares in exchange for 1,499,900 Class A ordinary shares (the “Share Exchange”). The 1,499,900 Class A ordinary shares issued in connection with the Share Exchange are subject to the same restrictions as applied to the Class B ordinary shares before the Share Exchange, including, among other things, certain transfer restrictions, waiver of redemption rights and the obligation to vote in favor of an initial business combination as described in the Prospectus.
For the year ended December 31, 2025, we had net income of $1,343,931 which consisted of general and administrative expenses of $827,300, offset by total interest income from our bank account and investments in Trust Account of $2,171,231 For the year ended December 31, 2024, we had net loss of $226,383, which consisted of general and administrative expenses of $587,106, offset by total interest income from our bank account and investments in Trust Account of $360,723.
For
the year ended December 31, 2023, we had net loss of $2,650, all of which consisted of formation and operating expenses.
The
Company’s liquidity
needs prior to the closing of IPO were satisfied through a payment from the Sponsor of $25,000 (see Note 5)
for the Founder Shares to
cover certain offering costs and the loan under an unsecured promissory note from the Sponsor of $244,603up to $350,000 (see
Note 5). As previously
disclosed on a Current Report on Form 8-K dated November 8, 2024, on November 12, 2024, on November 12, 2024,
the Company consummated
the IPO of 5,500,000 units (the “Units”). Each Unit consists of one Class A Ordinary Share (“Public
Share”) and
one right (“Public Right”) to receive one-tenth of one ordinary share upon the consummation of an initial
business combination.
The Units were sold at an offering price of $10.00 per Unit, generating gross proceeds of $55,000,000. The Company
granted the underwriters
a 45-day option to purchase up to 825,000 additional Units to cover over-allotments (the “Over-Allotment
Option Units”), if
any. The underwriters notified their partial exercise of the Over-Allotment Option on November 15, 2024, and
closed the Over-Allotment
Option on November 19, 2024. The total aggregate issuance by us of 6,000,000 units (which includes the partial exercise of the Over-Allotment
Option) at a price of $10.00 per
Unit resulted in a total gross proceeds of $60,000,000.
Following the IPO and the sale of the Private Placement Units, including the sale of the Over-Allotment Option Units, a total of $60,000,000 was placed in the Trust Account, and the Company had $1,888,753 of cash held outside of the Trust Account, after payment of costs related to the Initial Public Offering, and available for working capital purposes. The Company incurred $1,600,217 in transaction costs, including $600,000 of underwriting fees, the fair value of the representative shares of $675,000, and $325,217 of other offering costs. We intend to use substantially all of the funds held in the Trust Account, including any amounts representing interest earned on the Trust Account (less income taxes payable), to complete our Business Combination. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete our Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategies. Such working capital funds could be used in a variety of ways and could also be used to repay any operating expenses or finders’ fees which we had incurred prior to the completion of our Business Combination or to indemnify any of our officers or directors as required by law if the funds available to us outside of the Trust Account were insufficient to cover such expenses. On January 24, 2025, the Company repaid the Promissory Note in full. As of December 31, 2025, no amount was outstanding under the promissory note with our Sponsor.
As of December 31, 2025, we had marketable securities held in the Trust Account of $2,979,936 (including approximately $2,171,231 of interest income for the year ended December 31, 2025) consisting of U.S. Treasury Bills with a maturity of 185 days or less. We may withdraw interest from the Trust Account to pay taxes, if any.
The Company has incurred and expects to continue to incur significant costs to remain as a publicly traded company and to incur significant transaction costs in pursuit of the consummation of a Business Combination. We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business. However, if our estimate of the costs of identifying a target business, undertaking in-depth due diligence and negotiating a Business Combination are less than the actual amount necessary to do so, we may have insufficient funds available to operate our business prior to our initial Business Combination. Moreover, we may need to obtain additional financing either to complete our Business Combination or because we become obligated to redeem a significant number of our public shares upon completion of our Business Combination, in which case we may issue additional securities or incur debt in connection with such Business Combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our Business Combination. If we are unable to complete our Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account. In addition, following our Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations.
The
Company has incurred and expects to continue to incur significant professional costs to remain as a publicly traded company and to incur
significant transaction costs in pursuit of the consummation of a Business Combination. In addition, if the Company
is unable to complete
a business combination 1224 months from the closing of the IPO (or up to 18 months from the closing of the IPO if we extend the period
of time to consummate a business combination by the full amount of time),IPO, the Company’s board of directors would proceed
to commence
a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans
to consummate
a Business Combination will be successful. In connection with the Company’s assessment of going concern considerations
in accordance
with Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15,
“Disclosures “Disclosure
of Uncertainties Aboutabout an Entity’s Ability to Continue as a Going ConcernConcern,”, management has determined that
these suchconditions condition
also raisesraise substantial doubt about the Company’s ability to continue as a going concern. The management’s plan
in addressing
this uncertainty is through the Working Capital Loans (see Note 5). In addition, if the Company is unable to complete a
business combination
within the Combination Period (by November 12, 2025),Period, the Company’s board of directors would proceed to commence a voluntary liquidation
and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate a businessBusiness combinationCombination
will be successful within the Combination Period. As a result, management has determined that such an additional condition also raises
substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
Pursuant
to the underwriting agreement entered into on November 8,
2024, 2024,we issued to Maxim 247,500 Class A ordinary shares at the underwriterclosing was paid $600,000 forof the underwriting commissionsIPO (including
forsuch theClass partialA exerciseordinary of over-allotment option). Additionally, the Companyshares issued to the underwriterunderwriter,
the an“Representative aggregateShares”). of 270,000 Class
A ordinary shares including 22,500 shares asAs a result of the underwriter’s partial exercise of the underwriters’ over-allotment option aton theNovember
15, closing
of2024, thean IPO,additional for22,500 noRepresentative consideration,Shares subjectwere issued to the termsunderwriter. of the underwriting agreement. The underwriterMaxim has agreed not to transfer, assign
or sell
any such sharesRepresentative Shares until the completion of the initial Business Combination. In addition, the underwriter has agreed (and
its permitted
transferees will agree) (i) to waive its redemption rights with respect to such Representative Shares in connection with
the completion
of the Company’s initial Business Combination and (ii) to waive its rights to liquidating distributions from the
Trust Account
with respect to such Representative Shares if the Company fails to complete its initial Business Combination within the
Combination Period.
Merger Agreement
On May 23, 2025, the Company entered into the Merger Agreement with (i) Bioserica, (ii) PubCo, and (iii) Merger Sub.
Pursuant to the Merger Agreement, among other things, (i) the Company will merge with and into PubCo, the separate corporate existence will cease and PubCo will continue as the surviving corporation (the “Reincorporation Merger”), and (ii) the Merger Sub will merge with and into Bioserica and Bioserica will continue as the surviving company under the laws of the British Virgin Islands and become a wholly owned subsidiary of PubCo (the “Acquisition Merger”). Pursuant to the terms of the Merger Agreement, the aggregate consideration for the Acquisition Merger is $217,860,000, consisting of (i) $200,000,000, payable in the form of 20,000,000 newly issued PubCo Class B ordinary shares, valued at $10.00 per share; and (ii) $17,860,000, payable in the form of 1,786,000 newly issued PubCo Class A ordinary shares, valued at $10.00 per share (assuming that Bioserica would receive an aggregate of $12,500,000 investment from third parties prior to Closing).
The Merger Agreement contains customary representations, warranties and covenants of the parties thereto. The consummation of the proposed Merger is subject to certain conditions as further described in the Merger Agreement.
Concurrently with the execution of the Merger Agreement, Bioserica, PubCo, the Company and a shareholder of Bioserica (the “Supporting Shareholder”) entered into a voting and support agreement (“Voting and Support Agreement”) pursuant to which such the Supporting Shareholder has agreed, among other things, to vote in favor of the Acquisition Merger, the adoption of the Merger Agreement and any other matters necessary or reasonably requested by Bioserica, PubCo or the Company for consummation of the Acquisition Merger and the other transactions contemplated by the Merger Agreement. In addition, the Supporting Shareholder has agreed not to sell, assign, encumber, pledge, hypothecate, dispose, loan or otherwise transfer the shares of the Company owned of record and beneficially by such Supporting Shareholder or over which such Supporting Shareholder has voting power, prior to the earlier to occur of (a) the closing of the Acquisition Merger, (b) the termination of the Merger Agreement, and (c) written agreement of the Supporting Shareholder, on the one hand, and the Company and PubCo, on the other hand.
The
Company accountedaccounts for its Class
A ordinary shares subject to possible redemption in accordance with the guidance in ASC Topic480. 480,Class “Distinguishing
LiabilitiesA from Equity” (ASC 480). Ordinaryordinary shares subject to mandatory
redemption (if any) will beis classified as a liability
instrument and will beis measured at fair value. Conditionally redeemable ordinary shares (including
ordinary shares that featuresfeature redemption
rights that are either within the control of the holder or subject to redemption upon the occurrence
of uncertain events not solely within
the Company’s control) will beare classified as temporary equity. At all other times, ordinary shares will be
are classified as shareholder’s
stockholders’ equity. In accordance with ASC 480-10-S99, the Company classified theThe Class A ordinary shares feature certain redemption rights that are considered to be
outside of the Company’s control and subject to redemptionthe outsideoccurrence of permanentuncertain future events. In accordance with the SEC and its guidance
on redeemable equity asinstruments, thewhich has been codified in ASC 480-10-S99, redemption provisions are not solely within the control of thea
company Company.require Asordinary shares subject to redemption to be classified outside of Novemberpermanent 19,equity. 2024, givenGiven that the 6,000,000
Class A ordinary
shares (inclusive of the partial exercise of the underwriter’s over-allotment option) sold as part of the units
in theCompany’s IPO were issued with other freestanding instruments (i.e., rightsPublic Rights), the initial carrying
value of Class A ordinary shares classified
as temporary equity washas been allocated to the allocated proceeds determined in accordance with ASC 470-20.
The Company’s Class A ordinary shares are subject to ASC 480-10-S99. If it is probable that the equity instrument
will become redeemable,
the Company has the option to either (i) accrete changes in the redemption value over the period from the date
of issuance (or from the
date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption
date of the instrument
or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of
the instrument to equal
the redemption value at the end of each reporting period. The Company has elected to recognize the changes in
redemption value asin aadditional
paid-in chargecapital against(or retainedaccumulated earnings or,deficit in the absence of retained earnings, as a charge against additional paid-in-capital
paid-in capital) over an expected 12-month period, which is the initial
period leadingthat upthe Company has to complete a businessBusiness combination.Combination.
Subsequent to the IPO date, the accretion also includes the dividend and interest income earned in the Trust Account in excess of income and franchise taxes, if any.
In
November 2023, the FASB
issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which
requires the disclosure of
additional segment information. ASU No. 2023-07 is effective for fiscal years beginning after December 15,
2023, and interim periods within
fiscal years beginning after December 15, 2024. The Company isadopted currentlythis evaluatingguidance theon impactJanuary of1, adopting
ASU2025 2023-07.and there was no significant impact.
In
December 2023, the FASB
issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU 2023-09), which requires
disclosure of incremental
income tax information within the rate reconciliation and expanded disclosures of income taxes paid, among
other disclosure requirements.
ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. Early adoption is permitted.
Our management doesis notcurrently
evaluating believe the adoption ofthis ASU 2023-09to willdetermine have a materialits impact on ourthe financial statements andCompany’s disclosures.
JOBS Act
On April 5, 2012, the JOBS Act was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements for qualifying public companies. We will qualify as an “emerging growth company” and under the JOBS Act will be allowed to comply with new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We are electing to delay the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
Additionally, we are in the process of evaluating the benefits of relying on the other reduced reporting requirements provided by the JOBS Act. Subject to certain conditions set forth in the JOBS Act, if, as an “emerging growth company,” we choose to rely on such exemptions we may not be required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404, (ii) provide all of the compensation disclosure that may be required of non-emerging growth public companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (auditor discussion and analysis), and (iv) disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of five years following the completion of our initial public offering or until we are no longer an “emerging growth company,” whichever is earlier.
What changed in the latest 10-Q
Risk Factors
As smaller reporting company we are not required to make disclosures under this Item.
No wording changes found in this section.
Full comparison: every changed paragraph (0)
Management's Discussion & Analysis (MD&A)
Largest changes
“On May 20, 2026, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), which stated that because the stockholders’ equity of the Company reported on its Form 10-Q for the fiscal quarter ended March 31, 2026 was below the minimum of $2,500,000 stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1), the Company no longer complies with Nasdaq’s continued listing rules on The Nasdaq Capital Market. …”see in full comparison
“In January 2025, the FASB issued ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The FASB issued ASU 2024-03 on November 4, 2024. ASU 2024-03 states that the amendments are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. …”see in full comparison
“On November 4, 2024, the FASB issued ASU No. 2024-03, Expense Disaggregation Disclosures (“ASU 2024-03”). ASU 2024-03 amends ASC 220, Comprehensive Income to expand income statement expense disclosures and require disclosure in the notes to the financial statements of specified information about certain costs and expenses. ASU 2024-03 is required to be adopted for fiscal years commencing after December 15, 2026, with early adoption permitted. The Company is currently evaluating the potential impact of adopting the standard on its financial statements.”see in full comparison
“For the six months ended June 30, 2026, we had a net loss of $129,206, which consisted of general and administrative expenses of $93,187 and legal and professional expenses of $101,188, partially offset by interest income of $65,169. For the six months ended June 30, 2025, we had a net income of $793,141, which consisted of interest income of $1,294,055, partially offset by general and administrative expenses of $127,248 and legal and professional expenses of $373,666.”see in full comparison
For the three months endedsee in full comparisonMarchJune31,30, 2026, we had a net loss of$113,988,$15,218, which consisted of general and administrative expenses of$53,780$39,407 and legal and professional expenses of$93,400,$7,788, partially offset by interest income of$33,192.$31,977. For the three months endedMarchJune31,30, 2025, we had a net income of$413,202,$379,939, which consisted of interest income of$647,080,$646,975, partially offset by general and administrative expenses of$68,384$58,864 and legal and professional expenses of$165,494.$208,172.
In addition, if the Company is unable to complete a Business Combination within the Combination Period, the Company’s board of directors would proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate a Business Combination will be successful. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standardssee in full comparisonUpdate“Codification(“ASU”)Subtopic2014-15,205-40,“DisclosuresPresentation ofUncertaintiesFinancialabout anStatementsEntity’s Ability to Continue as a- GoingConcern,Concern”, management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The management’s plan in addressing this uncertainty is through the Working Capital Loans (see Note 5). In addition, if the Company is unable to complete a Business Combination within the Combination Period, the Company’s board of directors would proceed to commence a voluntary liquidation and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination Period. As a result, management has determined that such an additional condition also raises substantial doubt about the Company’s ability to continue as a going concern. The interim unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Full comparison: every changed paragraph (13)
On May 20, 2026, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), which stated that because the stockholders’ equity of the Company reported on its Form 10-Q for the fiscal quarter ended March 31, 2026 was below the minimum of $2,500,000 stockholders’ equity required for continued listing pursuant to Nasdaq Listing Rule 5550(b)(1), the Company no longer complies with Nasdaq’s continued listing rules on The Nasdaq Capital Market. In accordance with the Nasdaq listing rules, the Company had 45 calendar days to submit a plan to regain compliance and, if Nasdaq accepted the plan, Nasdaq could grant the Company an extension of up to 180 calendar days from the date of the letter to evidence compliance. On July 1, 2026, the Company submitted a plan to regain compliance and requested until November 16, 2026 to regain compliance. The plan proposed that in connection with the proposed Business Combination with Bioserica, all of the shareholders of Bioserica will become shareholders of PubCo, and Bioserica will become a wholly owned subsidiary of PubCo. Hence, the market value of the listed securities of PubCo would exceed the $75,000,000 requirement for listing on the Nasdaq Global Market under the Market Value Standard in compliance with Listing Rule 5405(b)(3). On July 17, 2026, the Company received a letter from Nasdaq accepting its compliance plan, and has been given an extension of up to November 12, 2026 to regain compliance with Rule 5550(b). In the event that the Company does not regain compliance on or before November 12, 2026, Nasdaq will provide written notification to the Company that its listed securities will be delisted and at that time, the Company may appeal the determination to a Hearings Panel. There is no assurance that the Company will regain compliance with Nasdaq’s continued listing requirement on or before November 12, 2026, or at all.
We have neither engaged in any operations nor
generated any operating revenues to date. Our only activities from September 3, 2021 (inception) through MarchJune 31,30, 2026 were organizational
activities and those necessary to prepare for the IPO and, following our IPO, searching for a Business Combination target and the negotiation
with potential targets for an initial Business Combination. We do not expect to generate any operating revenues until after the completion
of our Business Combination.
For the three months ended MarchJune 31,30, 2026, we
had a net loss of $113,988,$15,218, which consisted of general and administrative expenses of $53,780$39,407 and legal and professional expenses of $93,400,
$7,788, partially offset by interest income of $33,192.$31,977. For the three months ended MarchJune 31,30, 2025, we had a net income of $413,202,$379,939, which consisted of interest
income of $647,080,$646,975, partially offset by general and administrative expenses of $68,384$58,864 and legal and professional expenses of $165,494.$208,172.
For the six months ended June 30, 2026, we had a net loss of $129,206, which consisted of general and administrative expenses of $93,187 and legal and professional expenses of $101,188, partially offset by interest income of $65,169. For the six months ended June 30, 2025, we had a net income of $793,141, which consisted of interest income of $1,294,055, partially offset by general and administrative expenses of $127,248 and legal and professional expenses of $373,666.
Following the IPO and the sale of the Private
Placement Units, including the sale of the Over-Allotment Option Units, a total of $60,000,000 was placed in the Trust Account, and the
Company had $1,888,753 of cash held outside of the Trust Account, after payment of costs related to the Initial Public Offering, and available
for working capital purposes. The Company incurred $1,600,217 in transaction costs, including $600,000 of underwriting fees, the fair
value of the representative shares of $675,000, and $325,217 of other offering costs. We intend to use substantially all of the funds
held in the Trust Account, including any amounts representing interest earned on the Trust Account (less income taxes payable), to complete
our Business Combination. To the extent that our share capital or debt is used, in whole or in part, as consideration to complete our
Business Combination, the remaining proceeds held in the Trust Account will be used as working capital to finance the operations of the
target business or businesses, make other acquisitions and pursue our growth strategies. Such working capital funds could be used in a
variety of ways and could also be used to repay any operating expenses or finders’ fees which we had incurred prior to the completion
of our Business Combination or to indemnify any of our officers or directors as required by law if the funds available to us outside of
the Trust Account were insufficient to cover such expenses. On January 24, 2025, the Company repaid the Promissory Note in full. As March
31,of June 30, 2026, no amount was outstanding under the promissory note with our Sponsor.
As of MarchJune 31,30, 2026, we had marketable securities
held in the Trust Account of $3,006,138$3,032,747 (including approximately $26,202$52,811 of interest income for the threesix months ended MarchJune 31,30, 2026)
consisting of U.S. Treasury Bills with a maturity of 185 days or less. We may withdraw interest from the Trust Account to pay taxes, if
any.
As of MarchJune 31,30, 2026, the Company had $670,328
$633,724 of cash on hand and working capital of $279,570 .$237,744.
In order to fund working capital deficiencies
or finance transaction costs in connection with an intended initial Business Combination, our Sponsor or an affiliate of our Sponsor,
or certain of our officers and directors may, but are not obligated to, loan us funds as may be required (the “Working Capital Loan”).
If we complete our initial Business Combination, we would repay such loaned amounts. In the event that our initial Business Combination
does not close, we may use a portion of the working capital held outside the trust account to repay such loaned amounts but no proceeds
from our trust account would be used for such repayment. Up to $1,150,000 of such loans may be convertible into units at a price of $10.00
per unit at the option of the lender. The units would be identical to the Private Placement Units issued to our Sponsor. The terms of
such loans by our officers and directors, if any, have not been determined and no written agreements exist with respect to such loans.
We do not expect to seek loans from parties other than our Sponsor or an affiliate of our Sponsor as we do not believe third parties will
be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our trust account. As of March
31,June 30, 2026, no borrowing was outstanding under the Working Capital Loan.
In addition, if the Company is unable to complete
a Business Combination within the Combination Period, the Company’s board of directors would proceed to commence a voluntary liquidation
and thereby a formal dissolution of the Company. There is no assurance that the Company’s plans to consummate a Business Combination
will be successful. In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting
Standards Board (“FASB”) Accounting Standards Update“Codification (“ASU”)Subtopic 2014-15,205-40, “DisclosuresPresentation of UncertaintiesFinancial about
anStatements Entity’s Ability to Continue as a- Going Concern,Concern”, management has determined that these conditions raise substantial doubt
about the Company’s ability to continue as a going concern. The management’s plan in addressing this uncertainty is through
the Working Capital Loans (see Note 5). In addition, if the Company is unable to complete a Business Combination within the Combination
Period, the Company’s board of directors would proceed to commence a voluntary liquidation and thereby a formal dissolution of the
Company. There is no assurance that the Company’s plans to consummate a Business Combination will be successful within the Combination
Period. As a result, management has determined that such an additional condition also raises substantial doubt about the Company’s
ability to continue as a going concern. The interim unaudited condensed consolidated financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
We have no obligations, assets or liabilities,
which would be considered off-balance sheet arrangements as of MarchJune 31,30, 2026. We do not participate in transactions that create relationships
with unconsolidated entities or financial partnerships, often referred to as variable interest entities, which would have been established
for the purpose of facilitating off-balance sheet arrangements. We have not entered into any off-balance sheet financing arrangements,
established any special purpose entities, guaranteed any debt or commitments of other entities, or purchased any non-financial assets.
In January 2025, the FASB issued ASU 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40). The FASB issued ASU 2024-03 on November 4, 2024. ASU 2024-03 states that the amendments are effective for public business entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Following the issuance of ASU 2024-03, the FASB was asked to clarify the initial effective date for entities that do not have an annual reporting period that ends on December 31 (referred to as non-calendar year-end entities). Because of how the effective date guidance was written, a non-calendar year-end entity may have concluded that it would be required to initially adopt the disclosure requirements in ASU 2024-03 in an interim reporting period, rather than in an annual reporting period. The FASB’s intent in the basis for conclusions of ASU 2024-03 is clear that all public business entities should initially adopt the disclosure requirements in the first annual reporting period beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027.
On November 4, 2024, the FASB issued ASU No. 2024-03, Expense Disaggregation Disclosures (“ASU 2024-03”). ASU 2024-03 amends ASC 220, Comprehensive Income to expand income statement expense disclosures and require disclosure in the notes to the financial statements of specified information about certain costs and expenses. ASU 2024-03 is required to be adopted for fiscal years commencing after December 15, 2026, with early adoption permitted. The Company is currently evaluating the potential impact of adopting the standard on its financial statements.
Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our unaudited condensed consolidated financial statements.
ASPC insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding ASPC (13F)
None of the 59 investors we track reported a position in their latest 13F.